Kala Bio's Diagnostic Pivot: Structural Demand Real, But Program Evidence Absent

Kala Bio Finalizes Exclusive U.S. Distribution for Ophthalmology Genetic Testing

Kala Bio, Inc. and Virotek Inc. have finalized an exclusive U.S. distribution and reseller agreement for Virotek's ophthalmology genetic testing and screening program. Under the agreement, Kala will exclusively market and distribute the program in the United States for an initial one-year term, with continued exclusivity contingent on achieving commercial milestones. Virotek will maintain program infrastructure, kit supply, specimen processing, and clinical reporting, operating under a profit-sharing model once program costs are recovered. This partnership aims to address the U.S. genetic testing market, valued at $5.7 billion in 2025 and projected to reach $6.9 billion in 2026, particularly targeting inherited retinal diseases affecting approximately 1 in 3,450 individuals. The agreement also includes provisions for potential expansion into additional clinical verticals like oncology and preventive health.

• Kala Bio has secured exclusive U.S. distribution and reseller rights for Virotek's ophthalmology genetic testing program, effective September 4, 2026. The initial one-year term's exclusivity is tied to Kala achieving specific commercial milestones. Virotek will continue to manage the program's operational backbone, including infrastructure, kit supply, specimen processing, and clinical reporting. The financial arrangement involves a profit-sharing structure that becomes effective after Virotek recovers its initial program costs, reflecting a collaborative approach to market penetration and revenue generation.
• The partnership targets a significant market, with the U.S. genetic testing sector valued at $5.7 billion in 2025 and forecast to grow to $6.9 billion in 2026. Specifically within ophthalmology, the program addresses inherited retinal diseases, which are estimated to affect about 1 in 3,450 individuals. U.S. registry data highlights a substantial diagnostic demand, identifying over 40,000 new diagnoses of conditions such as retinitis pigmentosa, choroideremia, and achromatopsia over a seven-year period, underscoring the program's potential impact.
• Beyond the initial ophthalmology focus, the agreement provides Kala with a right of first refusal for future ophthalmology products and services from Virotek. Crucially, it establishes a framework for mutually agreed-upon expansion into additional clinical verticals over time. These potential areas include oncology, a preventive-health testing franchise, telehealth, and white-label distribution channels. This strategic foresight aligns with Kala's capital allocation strategy to build operating scale through staged, capital-efficient partnerships and address broader patient populations.

Kala's New Program: Advancing Inherited Retinal Disease Diagnosis

The clinical identification of inherited retinal diseases (IRDs) relies on a multimodal diagnostic framework that integrates functional, structural, and genetic assessments. No single biomarker is sufficient; rather, convergent evidence across modalities establishes diagnosis, disease staging, and therapeutic eligibility.

• Electroretinography (ERG): Full-field ERG (ffERG) and multifocal ERG (mfERG) are central to IRD diagnosis and functional staging. In retinitis pigmentosa (RP), the DA 0.01 b-wave amplitude — a rod-specific parameter — demonstrates a strong negative cross-sectional correlation with disease duration (r = −0.95, p < 0.0001), consistent with cumulative rod photoreceptor loss over time. Global ERG severity grading in a Palestinian RP cohort identified severe impairment in 40.8% of patients, with rod-specific classification identifying severe rod dysfunction in 32.4%. In Stargardt disease (STGD1), focal ERG (FERG) amplitude is significantly reduced (p < 0.0001) and shows a negative relationship with interruption of the ellipsoid zone (R = 0.54, p < 0.0001), establishing FERG as a reliable indicator of macular cone function.

• Optical Coherence Tomography (OCT) and Structural Imaging: Spectral domain OCT (SD-OCT) is used to evaluate photoreceptor integrity, particularly the ellipsoid zone (EZ). In STGD1, FERG amplitude shows a positive correlation with average macular thickness (AMT), while visual acuity is only weakly correlated with central macular thickness (CMT) (R = 0.12, p = 0.04), underscoring a functional–structural dissociation. In RP, best-corrected visual acuity (BCVA) and OCT-derived central macular thickness showed no significant correlation with ERG parameters, further reinforcing this dissociation. In early-stage STGD1, SD-OCT reveals disruption of the inner segment ellipsoid band accompanying an ovoid hypofluorescent foveolar lesion, preceding visible lipofuscin flecks or RPE atrophy.

• Fundus Autofluorescence (FAF): FAF imaging detects bisretinoid accumulation within photoreceptors and RPE cells in STGD1. Increased fundus autofluorescence and compromised photoreceptor integrity have been observed in the absence of atrophic retinal lesions in early-stage disease, implicating bisretinoid accumulation as an early pathological event. FAF and infrared imaging can detect lipofuscin flecks earlier than biomicroscopy, supporting their role as sensitive early-stage biomarkers.

• Genetic Testing (NGS, WGS, and Long-Read Sequencing): Molecular diagnosis is a cornerstone of IRD characterization. Next-generation sequencing (NGS) approaches — including targeted gene panels and whole exome sequencing — achieve a diagnostic yield of approximately 60%. Whole-genome sequencing (WGS) improves this rate by identifying elusive variants such as structural variants (SVs) and deep intronic variants (DIVs); in one cohort of 33 unsolved cases, WGS identified causative variants in 11 patients (33.3%). Long-read genome sequencing (LR-GS), producing reads of 10–20 kb, further resolves variants in low-complexity, high GC content, or structurally complex regions. Major causative genes identified across cohorts include ABCA4, CRB1, RPGR, USH2A, CEP290, EYS, PCDH15, and RHO, among others spanning more than 280 to 300 disease-associated genes.

• Functional–Structural Dissociation as a Diagnostic Signal: A consistent finding across RP and STGD1 is the dissociation between structural measures (visual acuity, macular thickness) and electrophysiological function. This dissociation underscores the importance of electrophysiology — particularly ERG — for diagnosis, prognostic counseling, and therapeutic eligibility assessment, especially in populations where structural changes may lag behind functional decline.

Kala's Strategic Play: Addressing Unmet Needs and Future Growth

Inherited retinal diseases (IRDs) represent a broad and genetically heterogeneous group of conditions linked to mutations in over 250 genes, creating substantial unmet need across multiple patient populations. The field has accelerated toward addressing gaps that traditional therapeutic approaches and outcome measures have failed to close.

• Patients with advanced-stage disease where photoreceptors are lost. Gene augmentation or gene editing therapies are limited in utility once significant cell loss has occurred. This population has been a focus of gene-agnostic strategies — including optogenetics, retinal cell reprogramming and replacement, neurotrophic support, and immune modulation — that aim to restore or preserve vision independent of the underlying genetic cause.

• Patients with rare or ultra-rare genetic subtypes underserved by gene-specific therapies. The great genetic heterogeneity of IRDs — with mutations detected across more than 90 different genes in a single cohort — limits the commercial and clinical feasibility of developing individualized gene therapies for each variant. Populations carrying mutations in genes such as RPGR, USH2A, CEP290, and ABCA4 are among those targeted in ongoing stage 2 and 3 trials, while gene-agnostic platforms are being developed to offer potential clinical benefit to all IRD patients regardless of genotype.

• Patients with early- to mid-stage disease where standard visual acuity endpoints are inadequate. Best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA) are described as useful "only across a very short window and in late stages of disease," rendering them unsuitable for patients whose foveal function remains primarily unaffected. This population requires alternative endpoints — including microperimetry, contrast sensitivity, color vision, and night vision assessments — to capture meaningful therapeutic benefit.

• Late-stage IRD patients being evaluated for optogenetic eligibility. Structural characterization using spectral-domain optical coherence tomography (SD-OCT) has shown that 46.3% of degenerate retinae in one cohort had preservation of inner retinal layers — including nerve fiber, ganglion cell, and inner plexiform layers — and may benefit from targeted cell-specific optogenetic gene therapy. Patients with indiscernible or disrupted inner layers are identified as candidates for non-cell-specific approaches targeting all surviving neurons.

• Blind patients with mutation-independent disease profiles. An investigator-initiated, open-label study in four blind retinitis pigmentosa patients with ABCA4 variants demonstrated that a synthopsin-based gene monotherapy delivered via intravitreal injection produced improvements in vision, shape discrimination, and mobility through 52 weeks — representing the first reported gene monotherapy capable of restoring vision in blind patients in a mutation-independent manner using an optogenetics platform.

The Global Burden of Inherited Retinal Diseases: A Growing Need

Population-level estimates of IRD prevalence and incidence vary by geography, but several recent national studies provide the most current benchmarks. A nationwide Swedish population-based register study covering 2006–2021 identified 6,544 IRD prevalent cases, estimating a cumulative overall prevalence of 62.6/100,000 persons and an overall average incidence rate of 3.4/100,000 individuals/year, with findings indicating a stable incidence over the past two decades. In Northern Finland, a retrospective analysis of patients diagnosed between 1996 and 2023 estimated a total IRD prevalence of 69.8/100,000 (1:1,432), with retinitis pigmentosa at 25.3/100,000, X-linked retinoschisis at 10.7/100,000, Usher syndrome at 8.9/100,000, choroideremia at 7/100,000, and cone or cone-rod dystrophy at 6/100,000. The Finnish population notably exhibits an enrichment of population-specific IRD-associated variants, resulting in a high overall prevalence and an increased prevalence of selected retinal subphenotypes such as retinoschisis, choroideremia, and Usher syndrome types 3 and 1.

Genetic architecture and disease distribution differ substantially across populations, complicating the derivation of a single global prevalence figure. In a large Pakistani cohort of 213 unrelated families (722 affected individuals), a precise molecular diagnosis was achieved in 171 pedigrees (80.3%), with causative variants identified in 60 different IRD-associated genes — a mutational landscape shaped heavily by endogamy and founder mutational events, differing substantially from European or Asian populations. A study of 123 IRD probands from understudied ethnic groups referred to Italian hospitals reported retinitis pigmentosa as the most represented phenotype (56%), followed by cone dystrophy (11%) and Leber congenital amaurosis (7%), with ABCA4 as the most frequently mutated gene (18%), followed by USH2A (9%) and RPGR (5%). In a Korean cohort of 100 patients clinically diagnosed with retinitis pigmentosa, definite causative genes were detected in 60/100 patients (60.0%), with USH2A the most common causative gene (14/60, 23.3%), followed by EYS (13/60, 21.7%) and RP1 (6/60, 10.0%).

Access to diagnosis and genetic characterisation remains uneven across global populations, with Indigenous and understudied communities facing particular gaps. A scoping review of IRDs in Indigenous Peoples worldwide, synthesising 73 studies (581 cases) from 24 countries published between 1974 and 2023, found that the most well-characterised population-specific IRD gene variants are those of Middle Eastern Bedouin populations, New Zealand Māori, and other Pacific peoples, enabled by dedicated programs. For most other global Indigenous groups, knowledge of relative prevalence and support needs remains limited. In Nigeria, a hospital-based study at the Guinness Eye Center Onitsha reported that 37 (0.6%) of 5,876 new patients had retinitis pigmentosa, with 6 (16.2%) patients blind and 22 (59.5%) with visual impairment, underscoring that detailed population-level prevalence and incidence data for many regions remain scarce.

Navigating the Future of Ophthalmic Genetic Diagnostics

The recent partnership between Kala Bio and Virotek to exclusively distribute an ophthalmology genetic testing program in the U.S. signals a strategic move into a critical and rapidly evolving segment of precision medicine. Inherited retinal diseases (IRDs) represent a significant unmet need, with genetic testing now recognized as fundamental for accurate diagnosis and, crucially, for determining eligibility for novel gene-directed therapies. This collaboration aims to streamline access to specialized diagnostic services, tapping into a U.S. market projected to reach nearly $7 billion by next year.

For Kala Bio, this agreement offers a compelling entry point into a high-growth area without the extensive upfront investment in test development. By leveraging Virotek's established infrastructure, Kala can immediately focus on market penetration and distribution. The strategic foresight to include provisions for expansion into oncology and preventive health further positions the company for broader diversification, acknowledging the widespread utility of genetic testing across various medical disciplines, from identifying hereditary cancer syndromes to guiding personalized prevention strategies.

However, the landscape of genetic diagnostics is not without its complexities. While next-generation sequencing panels offer a targeted and efficient approach, studies indicate diagnostic yields for IRDs typically fall within the 40-70% range. A substantial number of patients may still present with variants of uncertain significance (VUS) or no identifiable pathogenic mutations, necessitating further investigation, such as functional assays or more comprehensive whole-genome sequencing, which has shown superior detection of structural and intronic variants. These limitations, coupled with ongoing challenges in cost, reimbursement, and the need for standardized variant interpretation, underscore the importance of robust genetic counseling and a multidisciplinary approach to patient care. Success will hinge on effectively communicating the value proposition while managing expectations regarding diagnostic certainty and navigating the dynamic technological and regulatory environment.